Avdoralimab (IPH 5401) selectively blocks the C5a-C5aR1 interaction and its downstream signaling in human myeloid cells. In vitro, C5aR1 blockade with Avdoralimab (10-30 μg/mL) inhibits C5a-induced neutrophil activation. Avdoralimab blocks the neutrophil activation induced by very high concentrations of C5a. Avdoralimab also inhibits the C5a-induced migration of neutrophils in vitro[1].
In mice with a knock in for human C5aR1 (HuC5aR1 KI mice), Avdoralimab blocks the infiltration of neutrophils and monocytes, prevents albumin release in broncho-alveolar lavage fluid (BALF) and limits C5a-induced acute lung injury (ALI) histopathological features[1].
References:
[1]. Julien Carvelli, et al. Association of COVID-19 inflammation with activation of the C5a-C5aR1 axis. Nature. 2020 Dec;588(7836):146-150.